VZVladislav V Zhezha

Vladislav V Zhezha

*This is an algorithmically generated author record based on publicly available information.

Vladislav V Zhezha has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence of chronic kidney disease in different regions of the world, the main causes of its development, associated with increased risk of cardiovascular diseases and modern methods of early diagnosis (literature review)

    by V. V. Zhezha, E. M. Evsikov, N. V. Teplova, O. B. Kuzmin, M. V. Stolbova, В. В. Жежа, Е. М. Евсиков, Н. В. Теплова, О. Б. Кузьмин, М. В. Столбова

    Chronic kidney disease (CKD) is a serious public health problem in all regions and countries of the world. The frequency of CKD stages 3–5 without dialysis, according to large clinical studies, in patients in North America and European countries is from 10 to 21 %, as are the rates of detection of albuminuria and decreased SCF, and in 66–80 % it is accompanied by arterial hypertension. In hypertensive patients with CKD treated with chronic hemodialysis (CHD), the prevalence of cardiovascular diseases (CVD) and complications, including coronary heart disease (CHD) and heart failure (HF), is high and ranges from 36-39 %.Identification of the underlying causes and nephrological monitoring in patients with CKD and renal failure, according to researchers, help to carry out timely preventive and nephroprotective drug therapy and positively influence cardiovascular risk factors. The review provides a detailed analysis of the prevalence, causes, relationship with the risk of cardiovascular diseases and modern approaches to the early diagnosis of CKD. Recently, methods for determining serum and urinary biomarkers of renal tubular damage in patients with cardiorenal syndrome have been introduced into clinical practice for pre-clinical diagnostics of CKD and HF. It has been noted that elevated values of their levels are stronger predictors of subsequent adverse clinical events, such as hospitalization for HF decompensation, cardiac death, left ventricular assist device placement and heart transplantation than changes in serum creatinine. The review provides a detailed analysis of the prevalence, causes, association with cardiovascular risk, and current approaches to early diagnosis of CKD.

  • Urinary excretion of kidney damage biomarkers in hypertensive patients with chronic kidney disease, chronic heart failure, and with combined antihypertensive therapy and cardiac glycosides

    by V. V. Zhezhа, E. M. Evsikov, N. V. Teplova, O. V. Kuzmin, M. V. Stolbova

    Background. The combination of renal and heart failure is characterized as cardiorenal syndrome (CRS) and represents a significant clinical problem associated with an unfavorable prognosis for patients with arterial hypertension (HTN). Combination therapy, including antihypertensive and antiproteinuric drugs, as well as lipidlowering and antiplatelet agents, theoretically has the potential to improve cardiovascular and renal outcomes in patients with nephrosclerosis and chronic kidney disease (CKD). However, there is currently conflicting information regarding the role of cardiac glycosides (CGs) in promoting renal protection in patients with hypertension, stage C2 CKD, and chronic heart failure (CHF), and the safe administration of these drugs in patients with comorbid conditions is often challenging. Objective. To evaluate the effect of antihypertensive therapy with secondand third-generation beta-blockers (BB) in combination with angiotensin-converting enzyme inhibitors (ACE inhibitors) and diuretics with the addition of glycemic control (GCU) on signs of subclinical glomerular and tubular damage in patients with essential and nephrogenic hypertension, stages C2 and C3a of CKD, and persistent atrial fibrillation (PAF) combined with CHF with preserved ejection fraction (pEF) in functional classes I and II, based on the dynamics of albuminuria and excretion of urinary biomarkers of tubular damage, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1), over a 3and 6-month follow-up. Design and methods. The observational study included 44 patients (12 men and 32 women, aged 42 to 76 years, mean age 56,8 ± 9,4 years) with essential and nephrogenic hypertension (with chronic pyelonephritis outside of exacerbation), with C2 and C3a stages of CKD and with PAF in combination with CHFpEF (FC I-II). All patients were divided into 2 groups according to clinical indications. In the 1st group (n = 18), combined antihypertensive therapy with ACE inhibitors, β-blockers and diuretics was carried out with simultaneous administration of CG for heart rate (HR) control. In the 2nd group (comparison, n = 26), similar antihypertensive therapy was carried out without CG, and HR was controlled by β-blockers. At baseline, 3, and 6 months, the impact of the prescribed therapy on tubulointerstitial and glomerular kidney damage was assessed in both groups based on changes in urinary concentrations of the biomarkers NGAL, KIM-1, and albumin. Results. In the group of patients with hypertension, CKD, and PAF with CHFpEF receiving CGs, an increase in mean glomerular filtration rate (GFR) and a decrease in serum creatinine levels were observed after 3 and 6 months, compared with the comparison group. Moreover, CG therapy was associated with an increase in albuminuria in all patients, which was not observed in patients receiving combination antihypertensive therapy (ACE inhibitors, beta-blockers, and diuretics) without CGs. Conclusion. The use of CGs in combination with antihypertensive therapy had a positive effect on renal nitrogen excretion in patients with hypertension and pulmonary fibrosis with CHF and was characterized by a decrease in serum creatinine and, accordingly, an increase in mean GFR. However, it was also accompanied by an increase in albuminuria. These data indicate the need for an individualized approach to CGs prescribing in patients with pulmonary fibrosis and CHF combined with HTN and CKD.

  • Open Access

    Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension

    by O. B. Kuzmin, N. V. Buchneva, V. V. Belyanin, V. V. Zhezha, M. V. Stolbova

    Resistant arterial hypertension is characterized by failure to control target blood pressure despite long-term use of optimal or maximum tolerated doses of three different antihypertensive drugs, including diuretic. Patients with resistant hypertension are included in a group of people at high risk of cardiovascular and renal complications, including accelerated progression of chronic kidney disease with a more rapid transition to the final stage of the disease. Resistant hypertension is based on a salt-sensitive, volume-dependent form of hypertension, which usually occurs against the background of increased aldosterone production and normal or even decreased renin plasma activity. A key role in its formation is played by an increase of sodium reabsorption in the kidneys, associated with excessive activity of aldosterone-sensitive epithelial sodium channels (ENaC), which control the reabsorption of this ion in the distal segments of the nephron. Its assumed that in this pathological process, in addition to aldosterone, is also involved the small Rho GTFase Rac1 — regulatory G-protein, which can enter into a direct ligand-independent interaction with mineralcorticoid receptors, performing the function of a powerful nonsteroidal activator of the transmission of their intracellular signals. Based on controlled, randomized clinical trials, the optimal fourth drug to overcome resistance in such patients is the steroid mineralcorticoid receptor antagonist spironolactone. However, the inclusion of this drug in antihypertensive therapy not only fails to control blood pressure in a significant proportion of patients with resistant hypertension, but also significantly increases the risk of hyperkalemia, especially in people with impaired renal function. The review presents data on the pharmacodynamics and pharmacokinetics of new inhibitors of aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system baxdrostat and finerenone, as well as the results of clinical studies assessing the clinical effectiveness and safety profile of these drugs in patients with resistant hypertension.

  • Open Access

    New drugs for the treatment of resistant hypertension: nonsteroidal mineralcorticoid receptor antagonist finerenone and aldosterone synthase inhibitor baxdrostat

    by О. Б. Кузьмин, V. V. Belyanin, N. V. Buchneva, V. V. Zhezha, Л. Н. Ландарь, M. V. Stolbova

    The inclusion of spironolactone in antihypertensive therapy does not provide blood pressure (BP) control in the significant proportion of patients with resistant hypertension (HTN) and is accompanied by an increased risk of developing of hyperkalemia and complications associated with blockade of male and female sex hormone receptors. In this regard, a search is underway for new drugs that are not only capable of effectively controlling BP in this population, but also have a more favorable safety profile than their predecessors. The most promising are new drugs that selectively suppress the activity of aldosterone synthase-aldosterone-mineralcorticoid receptor hormonal system, the excessive activity of which underlies the formation of resistant HTN. The review presents data on the characteristics of pharmacokinetics and the results of the clinical studies obtained in patients with resistant HTN when assessing the effectiveness and safety of the use of the new nonsteroidal mineralcorticoid receptor antagonist finerenone and the selective aldosterone synthase inhibitor baxdrostat.


  • Open Access

    Refractory Arterial Hypertension: Features of Neurohormonal and Water-salt Imbalanceand Approaches to Antihypertensive Drug Therapy

    by O. B. Kuzmin, V. V. Zhezha

    Refractory arterial hypertension is characterized by a lack of control of target blood pressure, despite the prolonged use >5 antihypertensive drugs with different mechanisms of action, including longacting diuretic chlorthalidone and the mineralcorticoid receptor antagonists (spironolactone or eplerenone). The review presents the results of clinical studies devoted the elucidating peculiarities of the neurohormonal status and water-salt balance in such patients and developing new approaches to antihypertensive drug therapy based on them. According to these studies, individuals with refractory hypertension differ from patients with resistant hypertension with the higher of sympathetic nervous system activity and the absence of an increased of intrathoracic fluid volume, which indirectly indicates a significant decrease in the intravascular fluid volume. In this regard, the review focuses on the data obtained in assessing the clinical efficacy of sympatholytics clonidine and reserpine in patients with resistant and refractory hypertension, as well as renal sodium-glucose co-transporter type 2 inhibitors, which suppress the sympathetic nervous system activity and can be used to overcome refractory hypertension in patients with type 2 diabetes.


  • Open Access

    Refractory arterial hypertension: hyperactivity of the sympathetic nervous system, kidney and approaches to antihypertensive drug therapy

    by О. Б. Кузьмин, V. V. Zhezha, N. V. Buchneva, Л. Н. Ландарь

    Improving blood pressure (BP) control and reducing the risk of developing unfavorable cardiovascular and renal outcomes in patients with refractory hypertension (HTN) is an urgent problem of cardiology. According to clinical studies, patients with refractory HTN receiving intensive diuretic therapy with chlorthalidone and a mineralcorticoid receptor antagonist differ from patients with refractory HTN by a higher sympathetic nervous system (SNS) activity. Overactivity of sympathetic nerves may be one of the key pathogenetic factors that is involved in the kidney in the formation of refractory HTN, exerting a direct stimulating effect on the type 3 Na+ / H+ exchanger (NHE3) and type 2 sodium glucose cotransporter (SGLT2), which are involved in BP control by mechanism of pressure natriuresis. The review presents data on the peculiarities of sympathetic regulation of sodium tubular transport and the results of studies devoted the elucidating in the patients with resistant and refractory HTN the clinical efficacy of SGLT2 inhibitors glyflozins, sympatholytic reserpine and brain aminopeptidase A inhibitor firibastat, which suppresses the activity of central structures of SNS.


  • Uncontrolled Arterial Hypertension: Kidney, Neurohormonal Imbalance, and Approaches to Antihypertensive Drug Therapy

    by O. B. Kuzmin, N. N. Buchneva, V. V. Zhezha, S. V. Serdyuk

    Resistant and refractory arterial hypertensions are two distinct clinical phenotypes of uncontrolled arterial hypertension (AH), which differ in their sensitivity to antihypertensive drug therapy. The review presents data obtained in clinical studies devoted to elucidating the involvement of disorders of neurohormonal status and renal function in the formation of resistant and refractory arterial hypertension, to and the development of new approaches to increasing the effectiveness of antihypertensive therapy in these patient’s populations. The results of these studies have shown that in patients with uncontrolled arterial hypertension, despite prolonged intake ≥ 3 antihypertensive drugs with different mechanisms of action, including a diuretic, excess sodium reabsorption persists in the distal segments of nephron due to increased aldosterone activity and sympathetic nervous system hyperactivity. In this regard, special attention has been paid to the data of PATHWAY-2, PATHWAY-3 and ReHOT trials that in patients with resistant AH tested the clinical efficacy of spironolactone, amiloride, and antiadrenergic drugs bisoprolol, doxazosin and clonidine, suppressing activity of the sympathetic nervous system.


  • RESISTANT ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: PREVALENCE, PROGNOSTIC SIGNIFICANCE, REASONS AND APPROACHES TO ANTIHYPERTENSIVE THERAPY

    by O. Б. Кузьмин, V. V. Zhezha, Л. Н. Ландарь, O. A. Salova

    Arterial hypertension (AH) resistant to drug therapy is the phenotype of uncontrolled AH, in which patients receiving at least 3 antihypertensive drugs, including a diuretic, maintain blood pressure above the target level. Initially, the term refractory hypertension was also used to refer to resistant hypertension. Recently, however, refractory hypertension has been isolated into a separate phenotype of difficult to treat hypertension, which is defined as insufficient control of target blood pressure, despite the use of at least 5 different mechanisms of antihypertensive drugs, including long-acting diuretic and antagonist of mineralcorticoid receptors. Resistant hypertension is detected in 10–15 % of all hypertensive patients receiving drug therapy, and is often found in patients with chronic kidney disease. Hypertension can be a cause and/or consequence of kidney damage and is typical of most patients with chronic kidney disease. The lack of control of target blood pressure in a significant proportion of hypertensive patients with CKD who receive at least 3 antihypertensive drugs of different mechanisms of action indicates a lack of effectiveness of antihypertensive therapy, which not only accelerates the loss of renal function, but also significantly worsens the prognosis, contributing to such people risk of cardiovascular and renal complications. The review presents data on the prevalence, prognostic value of resistant hypertension in patients with chronic kidney disease, features of its formation and approaches to increasing the effectiveness of antihypertensive therapy in this patient population.


  • Open Access

    Beta-adrenoblockers of third generation as medicines for drug therapy of patients with chronic kidney disease

    by Oleg B Kuzmin, Vladislav V Zhezha, Vitaly V Belyanin, Natalya V Buchneva

    The review discusses the results of preclinical and clinical trials on the identification of nephroprotective action of β-blockers 3 generation carvedilol and nebivolol on models of hypertensive and diabetic nephropathy and patients with chronic kidney disease. It was concluded that nebivolol and especially carvedilol differs from its predecessors additional antioxidant and nephroprotective properties may be the drugs of choice from β-blockers for drug therapy of hypertensive patients with chronic kidney disease.

  • Open Access

    Early kidney damage in patients with arterial hypertension: prognostic value and approaches to nephroprotective therapy

    by O. B. Kuz’mIn, V. V. Zhezha, V. V. Belyanin, N. V. Buchneva

    Раннее повреждение почек у больных артериальной гипертензией: прогностическое значение и подходы к нефропротективной терапии